Straits Times Index
3,300.04 -3.15 (-0.10%) S&P 500
5,188.09 +7.35 (+0.14%) Dow
38,890.05 +37.78 (+0.10%) Nasdaq
16,335.99 -13.26 (-0.08%) Bitcoin USD
63,058.80 -106.56 (-0.17%) CMC Crypto 200
1,309.29 -55.84 (-4.09%)
LLY Jan 2025 260.000 call
- Benzinga
What About Eli Lilly's Drug For Early Alzheimer's? FDA Panel To Discuss Next Month
Tuesday, the FDA said it would convene an in-person meeting of the Peripheral and Central Nervous System Drugs Advisory Committee on Monday, June 10, 2024, to discuss Eli Lilly and Co’s (NYSE:LLY) donanemab for early symptomatic Alzheimer’s disease. The open public hearing portion of the meeting will be conducted virtually. The Phase 3 study submitted as part of this application, TRAILBLAZER-ALZ 2, is a double-blind, placebo-controlled study to evaluate the safety and efficacy of donanemab in pa
- Zacks
A Look at Pharma ETFs Post Q1 Earnings
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
- Insider Monkey
13 Best Stocks That Will Always Grow
In this article, we discuss the 13 best stocks that will always grow. To skip the detailed analysis of the current economic landscape, go directly to the 5 Best Stocks That Will Always Grow. At the Federal Reserve’s May 1 meeting, Chairman Jerome Powell focused on the Fed’s dual mandate of promoting maximum employment and […]
